Pancreatic Enzyme Replacement Therapy (PERT) Guidelines

Introduction to PERT

The American Gastroenterological Association recommends that all commercially available pancreatic enzyme replacement therapy (PERT) products in the United States are of porcine origin, making porcine-derived enzymes the preferred and only FDA-approved source for treating pancreatic insufficiency 1, 2, 3

The FDA-approved PERT products (Creon, Zenpep, Pancreaze, Pertzye, and Viokace) are derived from porcine pancreas and contain varying concentrations of lipase, amylase, and proteases 1, 4
These products are labeled based on their USP lipase content, which is the primary enzyme needed for fat digestion 1

Porcine pancreatic enzymes have been extensively studied and have demonstrated efficacy in treating exocrine pancreatic insufficiency (EPI) 2, 5
The enteric-coated formulations protect the enzymes from gastric acid degradation, allowing them to be released in the duodenum at pH >5.5 5
Mini-microspheres (1.0-1.2 mm) have shown higher therapeutic efficacy compared to larger microspheres 5, 6

There are no FDA-approved bovine pancreatic enzyme products for treating EPI 1, 3
Over-the-counter enzyme supplements (which might include bovine-derived products) should not be used as they are classified as dietary supplements only, with unstandardized dosing, unregulated efficacy, and unknown safety 1, 2

Untreated EPI results in maldigestion symptoms, nutritional deficiencies, poor quality of life, and increased mortality 1
Initial PERT dosing should be at least 40,000 USP units of lipase during each meal in adults and half that with snacks 1
PERT should be taken during meals to maximize mixing with food and digestion of nutrients 2
The different FDA-approved porcine enzyme products are generally considered equipotent at similar lipase dosages 3
Switching between different porcine enzyme products is typically based on insurance coverage rather than efficacy differences 1

Monitoring of fat-soluble vitamin levels is appropriate for patients on PERT 1
Success of PERT is measured by reduction in steatorrhea, weight gain, improvement in muscle mass and function, and normalization of fat-soluble vitamin levels 3

Enteric-coated pH-sensitive microspheres with a diameter of 1.0-1.2 mm are the optimal pancreatic enzyme replacement therapy formulation for patients with chronic pancreatitis and pancreatic exocrine insufficiency, as they protect enzymes from gastric acid degradation and ensure synchronized emptying with food, according to the Clinical Nutrition guideline 7
The enteric coating prevents pepsin and gastric acid from destroying the enzymes before they reach the duodenum, whereas conventional powder or tablet formulations are partially inactivated in the stomach and have been abandoned due to inferior efficacy, as stated by the Clinical Nutrition guideline 7
Mini-microspheres measuring 1.0-1.2 mm in diameter demonstrate higher therapeutic efficacy compared to larger 1.8-2.0 mm microspheres, as reported by the Clinical Nutrition guideline 7
These formulations disintegrate rapidly at pH >5.5 in the duodenum, ensuring enzyme availability precisely where digestion occurs, according to the Clinical Nutrition guideline 7

Adding proton pump inhibitors can help reduce bicarbonate production in chronic pancreatitis, which creates excessive duodenal acidity and denatures both endogenous and administered enzymes, as suggested by the Proceedings of the Nutrition Society guideline 8
Considering small intestinal bacterial overgrowth (SIBO) is essential, as it occurs in up to 92% of patients with pancreatic exocrine insufficiency and may require antibiotic treatment, according to the Proceedings of the Nutrition Society guideline 8
Verifying adequate dosing is crucial, as many patients are undertreated, and 70% of chronic pancreatitis patients continue experiencing steatorrhea-related weight loss due to insufficient enzyme dosing, as reported by the Proceedings of the Nutrition Society guideline 8

Non-enteric-coated formulations should be avoided, as they are less effective, according to the Clinical Nutrition guideline 7
Clinical symptoms of maldigestion, including steatorrhea, bloating, and abdominal discomfort, should be monitored, as stated by the Clinical Nutrition guideline 7